Comparative efficacy study of topical finasteride in androgenic alopecia

Comparative efficacy study of topical finasteride and topical minoxidil versus topical minoxidil alone in male patients with androgenic alopecia.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191203045592N2

Enrollment

Registered

2021-02-10

Start date

2021-02-19

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

androgenic alopecia. Androgenic alopecia

Interventions

Intervention 1: Intervention group: Is treated with topical solution of Minoxidil 5% + Finasteride 1% 1 cc twice daily for 12 weeks. Intervention 2: Control group: Use 1 CC of topical 5% minoxidil lot

Eligibility

Sex/Gender

Male

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Men 18-40 years old with moderate to severe androgenic alopecia. Patients should not be treated with oral finasteride or other anti-androgen therapy for the past 6 months. Willingness to participate in the study and fill out the informed consent form. Their diagnosis has been clinically proven and other causes of hair loss have been ruled out.

Exclusion criteria

Exclusion criteria: Patients with other types of alopecia such as alopecia areata or telogen effluvium. Any serious systemic disease Receiving systemic treatment for androgenic alopecia during the last 6 months.

Design outcomes

Primary

Measure	Time frame
Hair count. Timepoint: At the start of study and 12 weeks later. Method of measurement: Scalp & Hair Polarizing HMS System (KC Technology Company; Korea).;Hair thickness. Timepoint: At the start of study and 12 weeks later. Method of measurement: Scalp & Hair Polarizing HMS System (KC Technology Company; Korea).;Patient's satisfaction score. Timepoint: at the end of 12th week. Method of measurement: The standardized 7 point rating scale (–3 = greatly decreased, –2 = moderately decreased, –1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased).;Physician's assessment based on changes in standard photographs. Timepoint: at the end of 12th week. Method of measurement: The standardized 7 point rating scale (–3 = greatly decreased, –2 = moderately decreased, –1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased).	—

Measure

Time frame

Hair count. Timepoint: At the start of study and 12 weeks later. Method of measurement: Scalp & Hair Polarizing HMS System (KC Technology Company; Korea).;Hair thickness. Timepoint: At the start of study and 12 weeks later. Method of measurement: Scalp & Hair Polarizing HMS System (KC Technology Company; Korea).;Patient's satisfaction score. Timepoint: at the end of 12th week. Method of measurement: The standardized 7 point rating scale (–3 = greatly decreased, –2 = moderately decreased, –1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased).;Physician's assessment based on changes in standard photographs. Timepoint: at the end of 12th week. Method of measurement: The standardized 7 point rating scale (–3 = greatly decreased, –2 = moderately decreased, –1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGita Faghihi

Esfahan University of Medical Sciences

g_faghihi@med.mui.ac.ir+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026